These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prevention and Treatment of High-altitude Illness in Travelers.
    Author: Murdoch DR.
    Journal: Curr Infect Dis Rep; 2004 Feb; 6(1):43-49. PubMed ID: 14733848.
    Abstract:
    High-altitude illness is the collective term for acute mountain sickness (AMS), high-altitude cerebral edema (HACE), and high-altitude pulmonary edema (HAPE). These syndromes can affect unacclimatized travelers shortly after ascent to high altitude (especially higher than 2500 m). AMS is relatively common and usually is mild and self-limiting; HACE and HAPE are uncommon but life-threatening. Gradual ascent is the best strategy for preventing or minimizing high-altitude illness, although chemoprophylaxis may be useful in some situations. Acetazolamide remains the chemoprophylactic agent of choice, although other drugs, such as gingko biloba, are being investigated. Immediate descent remains the cornerstone of treatment for HACE and HAPE, although pharmacologic and hyperbaric therapies may facilitate this process.
    [Abstract] [Full Text] [Related] [New Search]